Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | GJB2 | P29033 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | CPB1 | P15086 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148761 | 1.00 | BCHE (0.36) | BCHEPTPN1ACHESLC6A2GJB2 | |
| SCHEMBL19479297 | 1.00 | BCHE (0.36) | BCHEPTPN1ACHESLC6A2GJB2 | |
| SCHEMBL19479353 | 1.00 | BCHE (0.36) | BCHEPTPN1ACHESLC6A2GJB2 | |
| SCHEMBL22050897 | 0.87 | PTPN1 (0.37) | BCHEPTPN1GJB2PTPN2PTPN11 | |
| SCHEMBL17777232 | 0.83 | — | — | |
| SCHEMBL17777234 | 0.83 | — | — | |
| SCHEMBL19491796 | 0.83 | — | — | |
| SCHEMBL17151668 | 0.83 | — | — | |
| SCHEMBL2012813 | 0.83 | BCHE (0.40) | BCHEPTPN1ACHESLC6A2GJB2 | |
| SCHEMBL2012812 | 0.83 | BCHE (0.40) | BCHEPTPN1ACHESLC6A2GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284420-A1 | E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE | GLYCOMIMETICS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284420-A1 | E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE | SELE, SELPLG, SELP | BCHE 2217/4885PTPN1 1471/4885ACHE 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.